Navigation Links
AFFiRiS AG: Capital Increase: AFFiRiS Brings Santo VC and MIG 11 on Board
Date:11/8/2011

us to all parties immediately, that there is a common understanding what the future development of AFFiRiS should look like as we implement the appropriate actions. We are delighted that Santo is appreciating AFFiRiS's potential by committing a substantial stake into the company."

Opportunities > Risks

Regarding his positive investment decision for AFFiRiS, Thomas Strüngmann explains: "We are excited about the opportunity to invest into this very promising biotech company. Seeing what Walter Schmidt and Frank Mattner have created and established with their top class team we remain highly impressed."

A further substantial argument for Santo to invest into AFFiRiS is related to recent developments in its key projects - in particular to the exciting progress of the ongoing Parkinson's project. Here, the aim is to deliver the world's first vaccine for Parkinson's disease - a project for which a Phase I safety and tolerability trial, supported by the American Michael J. Fox Foundation with almost USD 2 million, will start early 2012.The Parkinson's disease vaccine benefits from the company's experience in developing vaccines against Alzheimer's disease. In 2008, the company closed a licence agreement with GSK Biologicals, worth up to EUR 430 Mio. milestone-based payments.  

The basis for all these programmes is the company's AFFITOME® technology plus related know-how which allows the preclinical development of entire vaccine families with high specificity which are then moved quickly into clinical testing following the company's strategy called "clinical maturation".

Michael Motschmann, Management Chairman of the board of MIG Verwaltungs AG, on the most recent company developments: "AFFiRiS is an incredibly attractive investment. The company offers the unique combination of a validated platform technology and an approach of producing several vaccine candidates respectively, for diseases with unmet medical need and attr
'/>"/>

SOURCE AFFiRiS AG
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. AFFiRiS - MIG-Fonds Increases Investment by Euro 3 Million
2. GlaxoSmithKline and AFFiRiS Sign an Exclusive Licence and Option Agreement for Therapeutic Alzheimers Disease Candidate Vaccines
3. AFFiRiS AG: Atherosclerosis Vaccine Development Receives EU Support
4. AFFiRiS AG: 1st Place in Venture Capital & Private Equity Awards for MIG Fonds and AFFiRiS
5. AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimers Vaccine Candidate AD02 into Clinical Phase II Testing
6. AFFiRiS AG: Vaccination Against Hypertension is Development Project No. 4 and has Already Been Awarded an FFG Grant of up to EUR 1.2 Million
7. MGT Capital Investments Reports Second Quarter 2008 Financial Results and Provides Update on Recent Developments
8. TVM Capital, Signet Healthcare Partners and Paul Capital Healthcare Enter into euro 26 Million Financing of SpePharm
9. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
10. Sinobiomed Retains CB Capital Partners as Financial Advisor to Maximize Shareholder Value
11. Aegis Analytical Corp. Showcases Discoverant at Inaugural Venture Capital in the Rockies Fall
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... RIDGE, Tenn., July 24, 2014 -- A novel combination ... the Department of Energy,s Oak Ridge National Laboratory an ... for its unusual physical and electrochemical properties. , ... how oxygen affects the surface of a perovskite manganite, ... behavior. The new avenue to understand surface behavior could ...
(Date:7/24/2014)... sophisticated equipment, trained personnel, and detection dogs to ... attacks. A revolutionary new electronic chip with nano-sized ... much easier. , The groundbreaking nanotechnology-inspired sensor, devised ... ,s School of Chemistry and Center for Nanoscience ... Tracense, picks up the scent of explosives molecules ...
(Date:7/24/2014)... Research and Markets has announced ... 2014-2018" report to their offering.  ... the in vitro growth of plant or animal cells ... biopharmaceutical production. Cell culture is a crucial step in ... cell culture consumables are necessary for the in vitro ...
(Date:7/24/2014)... San Francisco, CA (PRWEB) July 24, 2014 ... Wednesday to be semi-finalists in Livestrong’s Big C Competition. ... Decisive Health are each headed to the semi-final round. ... in Livestrong’s exclusive three-month accelerator program, complete with mentoring ... country. , As part of the angelMD commitment ...
Breaking Biology Technology:ORNL study reveals new characteristics of complex oxide surfaces 2Nano-sized chip 'sniffs out' explosives far better than trained dogs 2Global Cell Culture Market 2014-2018: Key Vendors are Becton, Dickinson and Co, EMD, GE Healthcare, Lonza Group, Sigma Aldrich and Thermo Fisher Scientific 23 angelMD Startups Make Livestrong Big C Semi-finals 2
... Researcher Appreciation Event ... ... PHOENIX, Oct. 3 ThirdBiotech Inc., http://www.thirdbiotech.com, a biotechnology incubator ... Appreciation Event to be held on Thursday, October 23rd, 2008,between noon and ...
... http://www.amdl.com ),AMDL, Inc. (Amex: ADL ), a leading ... the US, today announced that the,Company will present at ... on Tuesday, October 7, 2008 at 10:30 a.m. ET. ... York Hotel in the Morosco Room., The Maxim ...
... Support R&D Efforts and Clinical Trials Advancing,the ... Oct. 3 Micromet, Inc. (Nasdaq:,MITI) ("Micromet" ... proprietary antibodies for the treatment of cancer, ... has closed its previously,announced $40 million private ...
Cached Biology Technology:First Annual Arizona Biotech Day Announced for October 23rd 2008 2First Annual Arizona Biotech Day Announced for October 23rd 2008 3AMDL, Inc. to Present at Maxim Group Growth Conference October 7, 2008 2AMDL, Inc. to Present at Maxim Group Growth Conference October 7, 2008 3Micromet Closes $40 Million Private Equity Placement 2Micromet Closes $40 Million Private Equity Placement 3Micromet Closes $40 Million Private Equity Placement 4
(Date:7/25/2014)... is a complex congenital central nervous system disease ... the neural tubes during the embryonic phase. Many ... fecal incontinence and neurocognitive retardation. Such problems decrease ... life. Researchers at Ankara Physical Medicine and Rehabilitation ... performance in children with SB, using the Pediatric ...
(Date:7/25/2014)... girls reach puberty is influenced by ,imprinted genes,a subset of ... gene. This is the first evidence that imprinted genes ... of this study were published today in the journal ... menarche, is a marker for the timing of puberty in ... varies between girls, is an inherited trait, and is linked ...
(Date:7/25/2014)... a molecular testing panel developed at UPMC greatly ... surgery for patients with thyroid nodules and cancer, ... Institute (UPCI), partner with UPMC CancerCenter., The test, ... other diagnostic testing agencies, improved the chances of ... percent, according to the study published this month ...
Breaking Biology News(10 mins):Could age of first period influence development of diseases in older women? 2Test increases odds of correct surgery for thyroid cancer patients 2Test increases odds of correct surgery for thyroid cancer patients 3
... European College of Neuropsychopharmacology (ECNP) is pleased to ... 2009 ECNP Neuropsychopharmacology Award in Basic Science Research ... into the neurochemical basis of substance addiction. ... in the field of neuropsychopharmacology and its closely ...
... Researchers have made significant advances in the treatment of metastatic ... treat successfully once it has started to spread according ... congress, ECCO 15 ESMO 34 [1], in Berlin on ... seen rapid and dramatic shrinking of metastatic tumours in patients ...
... research team at the National Institute of Standards and ... possible cancer therapy has uncovered a delicate balancing act ... says they should be. Just like individuals in a ... because they get close together, but not too close. ...
Cached Biology News:Trial of new treatment for advanced melanoma shows rapid shrinking of tumors 2Trial of new treatment for advanced melanoma shows rapid shrinking of tumors 3Therapeutic nanoparticles give new meaning to sugar-coating medicine 2
... 75 x ... recommended for immunohistochemistry of paraffin-embedded sections, ... at one end, markings ... normal procedures, precleaned, ...
1000X solution used for inducing CopyControl™ based vectors to high copy numbers...
Donor feline serum and plasma...
Request Info...
Biology Products: